Access to Innovation: BC Life Sciences Excellence and Leadership for Future Success

VANCOUVER, British Columbia- (BUSINESS WIRE) – The life sciences sector in British Columbia draws on excellence for a bright future in the province and beyond. Life Sciences BC will proudly demonstrate this at the two-day virtual summit “Access to Innovation” (February 16 and 17, 2022). Delegates will gain an insight into the latest discoveries and solutions coming from Canada’s fastest growing life sciences sector.

“During the pandemic, British Columbia’s life sciences campaign has earned international recognition for new technologies and treatments that improve the lives of people around the world,” said Ravi Colon, Minister of Labor, Economic Recovery and Innovation. “When we collaborate with British Colombians from all walks of life, we have heard very clearly that people are our competitive advantage. Our government is committed to investing in people and supporting the continued growth and diversification of the life sciences. Access to innovation emphasizes talent and innovation that will help us build the best BC for all. ”

The UK life sciences sector is ideally placed to stimulate growth not only in the provincial economy and healthcare system, but also nationally and globally. Contributions during the pandemic to mRNA vaccine technology, medical equipment, COVID therapeutics and more have put the life sciences sector of British Columbia firmly on the map. The theme of this year’s conference “Playing for Perfection” celebrates this by showcasing innovation in the sector to succeed in the economy and health after the pandemic. Industry experts and thought leaders will share their experiences of what it takes to commercialize the path from bench to bed, and where that excellence can lead us. Other sessions include processing and integrating data for research, building the hospital of the future, and supporting diversity and inclusion in the sector for the success of clinical trials and clinical equity.

From the inaugural program report celebrating the 75th anniversary of the National Research Council for Canadian Entrepreneurship Funding to Succeed in Innovation, to the success stories of companies in the UK life sciences, the Seventh Access to Innovation provides an unrivaled look at the vibrant life sciences sector. .

Speakers include Michael Martin, Chief Business Officer of Aurinia Pharmaceuticals, who will describe the path from research and development to the recent FDA approval anniversary for Lupkynis, the first FDA-approved oral therapy for lupus nephritis in adults.

During the Global MedTech and AI session, Dr. William Hunter, President and CEO of Canary Medical, and Dr. Peter Callis, Research Director and CEO, NanoMedicines Innovation Network, highlight recent advances in medical technology. In 2021, Canary Medical marked the first surgical implantation of a knee implant with a sensor that allows around the clock 7 hours a day after surgery to monitor patient progress. The lipid nanoparticle technology, developed by Dr. Callis, co-founder of Acuitas Therapeutics, has ensured the success of the Pfizer / BioNTech vaccine; Therapeutic mRNA agents are now ready to fight rare and infectious diseases, playing a role in preventive medicine and cancer treatment.

Quotes:

Wendy Herlbert, CEO and President, BC

“Our annual conference Access to Innovation never ceases to attract the best and brightest life sciences from our province. It is a place for an early insight into upcoming developments, cutting-edge solutions and leadership areas emerging from Canada’s fastest growing life sciences sector. Last year, more than 350 delegates heard from industry experts about how our fundamental excellence and world-leading research support innovation in the life sciences, growth and success in our province and beyond. ”

Dear Ravi Colon MLA, Minister of Labor, Economic Recovery and Innovation

“During the pandemic, British Columbia’s life sciences campaign has earned international recognition for new technologies and treatments that improve the lives of people around the world,” said Ravi Colon, Minister of Labor, Economic Recovery and Innovation. “When we collaborate with British Colombians from all walks of life, we have heard very clearly that people are our competitive advantage. Our government is committed to investing in people and supporting the continued growth and diversification of the life sciences. Access to innovation emphasizes talent and innovation that will help us build the best BC for all. ”

Peter Callis, research director and CEO of the innovation network NanoMedicines

«Basic science, interdisciplinary collaboration and efforts to translate scientific discoveries into practical application are key to innovation in the life sciences. Our lipid nanoparticle technology, which enables COVID-19 mRNA vaccines, such as the Pfizer / BioNTech vaccine, has evolved from very fundamental studies of the physical properties of lipids in biological membranes to systems with therapeutic potential, to enabling companies to produce and implement important therapeutic agents. But without basic curiosity-driven research, none of this would have happened. ”

Ali Ardokani, Founder and Managing Director of Novateur Ventures and Deputy Chairman of LSBC

“Our work at Novateur Ventures focuses on supporting life sciences innovation at startup with access to global and experienced technical resources that help the process from research and development through clinical trials to commercial success. It is always interesting to present success stories from our sector as inspiration for future entrepreneurs at events such as Access to Innovation. My experience as Deputy Chairman of the BC Board of Directors shows that sharing information in our community is very important for both inspiration and information. ”

Major sponsors

AbCellera

Gowling WLG (Canada) LLP

Deloitte Ltd.

Sponsors of the session

AstraZeneca Canada Inc.

Michael Smith Health Research BC

Aurinia Pharma Us Inc.

Novateur Ventures Inc.

Kampugen

Oyen Wiggs Green & Mutala LLP

The genome of British Columbia

Providence Health

IRICoR

STEMCELL Technologies Canada Inc.

Network sponsor

Event support

Innovative Medicines Canada

Canadian Supercluster of Digital Technologies

Please register at Access to innovation – building on excellence: a bright future for BC Life Sciences: https://lifesciencesbc.ca/event/access-to-innovation-2022/

About the life sciences BC

Life Sciences BC is a non-profit non-governmental association that supports and represents the life sciences community of British Columbia through leadership, investment and partnership promotion, and the advancement of our world-class science and industry.

The sectors of life sciences, from biopharmaceuticals and medical technologies to digital healthcare and medical devices, are integrated into our organization and everything we do, ensuring that no sector of life sciences works in isolation – and that all sectors come together in integrated, complementary and coordinated fashion.

During the year BC Life Sciences implements many programs and projects in support of these sectors. These include public policy initiatives that promote links between global industry and our local organizations, raise the profile of our industry internationally and thus foster investment and global partnership opportunities, and contribute to the economic development of British Columbia through science. of life.

About the life sciences sector of BC

BC is home to the fastest growing life sciences sector in Canada, and our reputation is global. Recently, Vancouver was named the leading ecosystem of startups in life sciences in Canada in 2021. Startup Genome ranked Vancouver 21st out of 280 global ecosystems, including it as the only Canadian city in the top 25.

As you also know, we exceed GDP growth in the life sciences of Canada (data for 2018) and hire more than 18,000 employees (data for 2020) with above-average salaries. During 2020, Britain’s biotech companies more than doubled revenue from the four major deals compared to 2019.

Leave a Comment